» Articles » PMID: 31396670

Prediction of Thrombosis Risk in Patients with Paroxysmal Nocturnal Hemoglobinuria

Overview
Journal Ann Hematol
Specialty Hematology
Date 2019 Aug 10
PMID 31396670
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hemolytic disease with thrombosis as a major complication. The mechanism of thrombosis and related risk factors in PNH patients are still not well characterized. We retrospectively enrolled 99 patients with newly diagnosed PNH at our institute from 2011 to 2016. According to binary logistic regression model analysis, we first identified four baseline clinical risk factors which may be associated with incidence of thrombosis in the PNH cohort, including PNH clone sizes (fluorescent aerolysin of neutrophil) ≤ 80 (OR 1.056, 95%CI 1.016-1.097, P = 0.005), hemoglobin ≤ 75 g/L (OR 4.202, 95%CI 0.984-17.954, P = 0.053), platelet > 100 × 10/L (OR 6.547, 95%CI 1.490-28.767, P = 0.013) and rs495828 = G (OR 5.243, 95%CI 1.314-20.916, P = 0.019). These independent risk factors were combined together to develop a risk model to evaluate thrombosis risk (AUC = 0.756, 95%CI 0.607-0.905, P < 0.001). Our risk model revealed a higher cumulative incidence of thrombosis and an earlier thrombosis events in PNH patients with high risk (risk score ≥ 23) compared with those with low risk (risk score < 23, P < 0.001 and P = 0.043, respectively). Although with some limitations, we set up a prediction model for thrombosis risk in patients with PNH for the first time, but it needed to be verified in a prospective study with larger patients and longer follow-up time in the future.

Citing Articles

Thrombosis in Paroxysmal Nocturnal Hemoglobinuria (PNH): From Pathogenesis to Treatment.

Kokoris S, Polyviou A, Evangelidis P, Grouzi E, Valsami S, Tragiannidis K Int J Mol Sci. 2024; 25(22).

PMID: 39596172 PMC: 11594924. DOI: 10.3390/ijms252212104.


Comparison of human leukocyte antigen in patients with paroxysmal nocturnal hemoglobinuria of different clone sizes.

Zhang Z, Hu Q, Yang C, Chen M, Han B Ann Hematol. 2024; 103(6):1897-1907.

PMID: 38616191 DOI: 10.1007/s00277-024-05740-w.


[Expert consensus on clonal screening and monitoring of complement inhibitor therapy in paroxysmal nocturnal hemoglobinuria (2024)].

Zhonghua Xue Ye Xue Za Zhi. 2024; 45(2):109-114.

PMID: 38604785 PMC: 11078681. DOI: 10.3760/cma.j.cn121090-20230927-00145.


Paroxysmal nocturnal hemoglobinuria-related thrombosis in the era of novel therapies: a 2043-patient-year analysis.

Gurnari C, Awada H, Pagliuca S, Dima D, Ullah F, Kawashima N Blood. 2024; 144(2):145-155.

PMID: 38513233 PMC: 11830967. DOI: 10.1182/blood.2024023988.


Swiss Survey on current practices and opinions on clinical constellations triggering the search for PNH clones.

Rovo A, Gavillet M, Drexler B, Keller P, Schneider J, Colucci G Front Med (Lausanne). 2023; 10:1200431.

PMID: 37564039 PMC: 10410560. DOI: 10.3389/fmed.2023.1200431.